Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease
- 11 May 2019
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 150 (2) , 218-230
Abstract
Previous studies have indicated the potential of cerebrospinal fluid (CSF) α‐synuclein (α‐syn) to be an additional biomarker for improving differential diagnosis of Alzheimer’s disease (AD). We evaluated α‐syn diagnostic performance across a well‐characterized patient cohort with long‐term follow‐up. For this purpose, CSF α‐syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI‐AD; n = 32), 24 MCI cases due to Lewy body disease (MCI‐LBD; n = 24) and control subjects (Ctrl; n = 18). CSF α‐syn levels discriminate between the four groups. There were higher α‐syn levels in MCI‐AD patients and lower levels in MCI‐LBD patients. The combination of α‐syn and P‐tau resulted in a specificity of 99% and a sensitivity of 97% for MCI‐AD. MCI‐AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P‐tau and α‐syn compared to the MCI‐AD patients without psychotic symptoms (n = 23). We conclude that adding CSF α‐syn to central core AD biomarkers improves an early differential diagnosis of MCI‐AD from other forms of MCI.Open Science Badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. imageKeywords
Funding Information
- European Regional Development Fund
- Instituto de Salud Carlos III
- Instituto de Salud Carlos III (CPII1600011)
This publication has 39 references indexed in Scilit:
- The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosisAlzheimer's Research & Therapy, 2014
- Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s diseaseAlzheimer's Research & Therapy, 2014
- The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s DiseasePLOS ONE, 2013
- CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s diseaseActa Neuropathologica, 2013
- Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of DementiaClinical Nuclear Medicine, 2013
- Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An UpdateBiomarkers in Medicine, 2012
- Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohortNeurology, 2012
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyThe Lancet Neurology, 2011
- Revised Criteria for Mild Cognitive Impairment: Validation within a Longitudinal Population StudyDementia and Geriatric Cognitive Disorders, 2006
- Diagnosis and management of dementia with Lewy bodiesNeurology, 2005